Press Release: Professor Sir Jonathan Van-Tam joins Reset Health

Press Release‍

Professor Sir Jonathan Van-Tam joins Reset Health

At Reset Health, Sir Jonathan will bring unparalleled expertise in public health, pharmaceuticals, and governmental policy, with strategic insight drawn from decades at the forefront of life sciences and public health.

London, England, Date 17th October 2025

Reset Health is pleased to announce that Professor Sir Jonathan Van-Tam has joined Reset Health as a member of its Advisory Board.

Professor Sir Jonathan brings extensive experience in public health, government, academia, and the pharmaceutical industry. As Deputy Chief Medical Officer to HM Government from 2017 to 2022, he played a key role in shaping the UK's response to the COVID-19 pandemic. He was instrumental in the acquisition and rollout of vaccines in the UK and was knighted by Her late Majesty the Queen in 2022 for his services to public health. Throughout his career he has led major global health initiatives in partnership with the World Health Organisation and the former Public Health England.

In the pharmaceutical sector, Sir Jonathan has held senior leadership positions at SmithKline Beecham (now part of GSK), Roche, and Aventis Pasteur MSD (now part of Sanofi). A distinguished academic, he is the former Pro-Vice Chancellor of the University of Nottingham.

Sir Jonathan said:
“The UK and many other nations face a future where the number of years people will live with chronic diseases and disability at the end of their lives will grow very substantially over the next two decades. At the same time, in the UK, the NHS faces very substantial challenges and needs rapid innovation and reform. Companies such as Reset Health have a critical role to play in this journey and I look forward to working with this excellent team to have real impact.”

David Wong, Executive Chairman at Reset Health, said:
"We are pleased to welcome Sir Jonathan as we reach an inflection point in our corporate journey. We transitioned from four years of development and evidence gathering to a rapid growth phase, selecting the right contracts and focusing on delivery and execution to establish the best clinical care models for chronic diseases. Sir Jonathan’s deep understanding of industry dynamics, regulatory frameworks, and global health challenges will help Reset Health navigate complex healthcare landscapes, market access, and policy engagement with strategic insight drawn from decades at the forefront of life sciences and public health.”

About Reset Health‍

Reset Health (www.resethealth.clinic) is an integrated chronic care specialist delivering end-to-end digital, scalable solutions for the management of chronic diseases including obesity, Type 2 diabetes, and dementia using evidence-based medical science and the latest therapies and interventions. Reset combines its Reset Technology Platform (RTP) with disease-specific, clinical care pathways to develop integrated care models.

Roczen (www.roczen.com), Reset’s integrated care model for metabolic health, is used in conjunction with new anti-obesity medications, GLP-1s and GIPs, to enhance health outcomes of patients with obesity and associated co-morbidities. Reset Health is regulated by the Care Quality Commission and following evaluation by the National Institute of Health and Care Excellence (NICE) has a time-limited recommendation for early use within the NHS until March 2028, while further evidence is gathered.

Roczen is the provider of obesity and Type 2 Diabetes care across the UK, Europe and Malaysia where its integrated care models are available to over 18 million patients, working with governments, employers, insurers, private providers and health systems.